Short communication

No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi

A.B. Ibarz-Pavon a,⇑, N. French a,b

a Centre for Global Vaccine Research, Institute of Infection & Global Health, University of Liverpool, United Kingdom
b Malawi-Liverpool-Wellcome Trust Laboratories, Blantyre, Malawi

A R T I C L E   I N F O

Article history:
Received 27 October 2017
Received in revised form 19 March 2018
Accepted 3 April 2018
Available online 7 April 2018

Keywords:
Viral load
CD4+ T-cell
PCV7
HIV-infected
Malawi

A B S T R A C T

Vaccination has been associated with a transient increase in viremia in HIV-infected individuals, although contradicting evidence persist in the literature. As part of a randomized placebo-controlled efficacy trial of the PCV7 in Malawi, we collected viral load and CD4+ T-cell counts from 237 adults who received two doses of vaccine or placebo, administered 4 weeks apart. Analyses were conducted separately for cART and non-cART users. Our analysis show no difference in viral loads between vaccine and placebo groups, regardless of cART use. Viremia decreased from 4.1 to 2.9 log_{10} copies/mL (p < 0.0001) among those using cART, consistent vaccine and placebo groups, but no changes were seen among the non-cART cohort. CD4+ T-cell counts remained unchanged regardless of cART use, or allocation to vaccine or placebo.

We concluded that there was no evidence of detrimental effects of PCV7 administration on viral load or CD4+ T-cell counts six months after vaccination with PCV7.

© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Streptococcus pneumoniae remains one of the biggest health threats in sub-Saharan Africa and, particularly, to the HIV infected population [1], but can be partly prevented with pneumococcal conjugate vaccines (PCV) [2], which have been effective in reducing the burden of disease among both HIV-infected and non-infected individuals, as well as providing indirect protection among those unvaccinated [2–5], and are recommended by policy-making bodies [6–8]. Immunization is considered safe, but several vaccines recommended for HIV+ patients have been linked to short-term increases in plasma viral loads (VL) [9–11], although this finding is inconsistent [12–15]. Immunization of HIV+ patients with pneumococcal polysaccharide vaccine was associated with transient increased viremia in a study conducted before combination Antiretroviral Therapy (cART) was available [16], but subsequent studies failed to corroborate this finding [14,17,18]. Three studies measured the impact of PCV and found no evidence of increases on VL, independently of cART [3,4,14]. Here, we analysed data collected during a double-blind randomized placebo-controlled trial evaluating the efficacy of the PCV7 among Malawian adults [2]. A post-hoc analysis of that study showed an excess mortality among the HIV+ PCV7-vaccinated subgroup who did not receive cART. We hypothesised that PCV7 might have a detrimental effect on HIV control, and report a comparison of changes in VL and CD4+ T-cell counts post-vaccine between two groups: those who received cART, and those who did not. cART use in our cohort was primarily determined by date of recruitment, with public funded cART becoming available two years after recruitment started.

2. Methods

The methods of this study are described elsewhere [2]. Briefly, individuals were enrolled following an episode of invasive pneumococcal disease. They received two doses of either PCV7 or a placebo, administered four weeks apart. Blood samples were collected at enrolment, before vaccination, and six months later. A total of 496 patients were recruited for the original trial, of which 439 (88.5%) were HIV+. Of these, 220 received the PCV7, and 219 a placebo. There were 136 (31.0%) deaths, 64 (47.1%) of which occurred within 6 months of recruitment, and 55 (86%) of these occurred among non-cART receivers. Sixty-seven (14.6%) HIV+ patients were lost to follow-up, of which 30 (44.8%) were lost within 6 months, of
which 27 (90%) were on the non-cART group. The study was approved by the College of Medicine Research and Ethics committee (protocol number 99/00/101).

For this analysis, we included 237 HIV+ cases for whom VL data at enrolment and at 6-months follow-up were available (Table 1). Analyses were conducted separately for individuals receiving cART, defined by already being on cART at enrolment or commencing it at any point between the baseline and follow-up sample being taken, and those who did not receive cART at any point between samplings. Normally-distributed variables are expressed as mean and standard deviation, and non-normally distributed ones are defined by median and interquartile range. Categorical variables were compared using Pearson's Chi-squared or Fisher's exact test. Student's t-test, and Wilcoxon Rank-Sum test were used for continuous variables. VLs and CD4+ T-cell counts were log10-transformed to approximate a normal distribution, and mean values between baseline (t0) and at 6-months (t6), and between and within vaccine and placebo groups were compared using a two-tailed paired and unpaired Student's t-test respectively. Statistical significance was set at p < 0.05. Analyses were conducted with StataV.12.1 (STATA Corp, TX, USA).

3. Results

Of the 439 HIV+ individuals recruited for the original clinical efficacy trial, 237 provided both t0 and t6 blood samples. Seventy-nine (33.3%) were on cART at some point between samplings, of which 32 (40.5%) were on cART at enrolment: 17 on the vaccine and 15 on the placebo arm, and 47 (21 in vaccine and 26 in placebo) started within 6 months of recruitment (Table 1). The mean times to cART commencement among these were 108.6 ± 62.1 and 93 ± 52.9 days for placebo and vaccine arms respectively (p = 0.365).

For both, cART and non-cART subgroups, participants in the vaccine and placebo arms were similar in regard of age, gender, and t0 VL and CD4+ T-cell counts. The mean time between t0 and t6 sampling was 184.5 ± 9.2 days, with no differences in regard of cART use (184.7 ± 8.8 on cART users vs. 184.3 ± 9.4 non-cART), and vaccine or placebo group (184.8 ± 9.2 and 184.2 ± 9.2 respectively).

There were no significant differences on VL baseline values between vaccine and placebo groups at t0 nor at t6 in either those receiving cART (t0 p = 0.308, t6 p = 0.274), nor on those not on cART within the sampling period (t0 = 0.100; t6 p = 0.121). Among those receiving cART, we observed a reduction on VL between t0 and t6, from 4.1 to 2.9 log10 copies/mL (diff 1.2 [0.89–1.51] p < 0.0001), which was consistent in vaccine (diff 1.18 [0.73–1.62] p < 0.0001) and placebo diff 1.22 [0.79–1.65] p < 0.0001) groups. This reduction was not observed among those not on cART.

Among the cART group, the number of individuals with undetectable VL (VL < 400 copies/mL) increased from 16 (42.1%) at t0 to 31 (81.6%) at t6 among vaccine recipients, and from 14 (34.2%) to 31 (75.6%) in the placebo. Among the non-cART group, 4 (4.8%) and 2(2.4%) vaccine recipients had undetected VLs at t0 and t6 respectively. One patient presented a VL < 400 cell/mL at both sampling points in the placebo group.

CD4+ T-cell counts were no different between vaccine and placebo groups at t0 and t6 regardless of cART treatment subgroup. Those receiving cART had an average increase of 55.7 CD4+ T-cell counts at t6 compared to t0 (p < 0.0001), which was consistent in vaccine (diff 60.6 p = 0.0004) and placebo (51.4 p = 0.0042) arms. No significant changes were observed between groups among those not on cART.

4. Discussion

Results show no evidence of a PCV7-induced change on either VL or CD4+ T-cell counts in HIV+ adults six months after receiving two doses of PCV7, consistent with published studies [3,4,14], which reassures us of our findings despite the fact that the sample size in all subgroups is relatively small and could have masked the effects. The reduction on VL detected among those receiving cART could be explained by use of cART, and was comparable in vaccine and placebo groups. We undertook this analysis looking for evidence of VL resetting resulting from vaccination that might provide an explanation for the observed increased mortality among those on the non-cART vaccine group in the original study [2], and found no evidence. We cannot exclude earlier changes in VL that other reports have suggested [11,19], but are reassured that there are no long-term detrimental effects on HIV infection or its control among HIV+ patients receiving cART. We cannot rule out the possibility that vaccine-induced increases in VL within the first 6 months of enrolment, which we did not measure, might have contributed to early deaths. However, in our population, these individuals presented a lower baseline CD4+ T-cell counts

### Table 1

Population characteristics and changes in CD4+ T-cells and Viral Loads pre-and post-intervention.

|                          | All population | ON cART (n = 79) | p value | NOT ON cART (n = 158) |
|--------------------------|----------------|------------------|---------|-----------------------|
|                          | Vaccine (n = 83) | Placebo (n = 75) |         | Vaccine (n = 83)      | Placebo (n = 75) |
| Patients included n (%)  | 237            | 38 (16.0)        | 41 (17.3)| 83 (35.0)             | 75 (31.6)       |
| Age, mean (SD)           | 34.4 (9.7)      | 36.9 (7.8)       | 35.5 (10.1)| 33.3 (10.7)          | 33.8 (9.1)       |
| Male gender, n (%)       | 95 (40.1)       | 8 (21.1)         | 13 (31.7)| 42 (50.6)             | 32 (42.7)       |
| Total receiving cART at any point between samplings | 79 (33.3) | 38 | 41 | NA | NA |
| On cART at enrolment, n (%) | 32 (40.5) | 17 (44.7) | 15 (36.6)| NA | NA |
| Started cART within 6 months of enrolment, n (%) | 47 (59.5) | 21 (55.3) | 26 (63.4)| NA | NA |
| VL and CD4 COUNTS AT ENROLMENT (t0) | | | | | |
| CD4, median (range), cells/L | 192 (7–9380) | 181 (32–573) | 191 (23–626) | 0.810 | 245 (40–835) | 183 (7–938) | 0.194 |
| Missing data, n (%)      | 22 (9.2)        | 3 (7.9)          | 6 (14.6)| 8 (9.6)               | 5 (6.7)         |
| Viral load, mean (SD), log10 copies/mL | 4.6 (1.1) | 4.0 (1.3) | 4.2 (1.3) | 4.7 (0.8) | 4.9 (0.8) | 0.100 |
| VL > 5log10 copies/mL, n (%) | 107 (45.15) | 16 (42.1) | 15 (36.6) | 39 (47.0) | 37 (49.3) | 0.768 |
| Undetectable VL (<400 copies/mL, n (%) | 35 (14.8) | 16 (42.1) | 14 (34.2) | 4 (4.8) | 1 (1.3) | 0.370 |
| VL and CD4 COUNTS AT 6 MONTHS (t16) | | | | | |
| CD4, median (range), cells/L | 229 (3–2000) | 287 (81–770) | 247 (23–616) | 0.332 | 238 (8–2000) | 199 (3–824) | 0.009 |
| Missing data, n (%)      | 24 (10.1)       | 4 (10.5)         | 1 (2.4)| 11 (13.3)            | 8 (10.7)        |
| Viral load, mean (SD), log10 copies/mL | 4.2 (1.2) | 2.8 (0.7) | 3.0 (0.9) | 4.8 (0.7) | 4.9 (0.7) | 0.121 |
| VL > 5log10 copies/mL, n (%) | 90 (38.0) | 2 (5.3) | 3 (7.3) | 0.708 | 42 (50.6) | 43 (53.7) | 0.397 |
| Undetectable VL (<400 copies/mL), n (%) | 65 (27.4) | 31 (81.6) | 31 (75.6) | 0.591 | 2 (2.4) | 1 (1.3) | 1.00 |
(117 cells/μL [2–753]), and higher VLs (4.9 log10 copies/mL) than those who survived, consistent with a higher risk of death independent of vaccine administration. Those who were lost to follow-up within 6 months could not be included in our analysis, as they would not have provided the second sample. The majority of these subjects were not receiving cART, and while their baseline VL and CD4+ T-cell values were not significantly different from those who remained in the study (data not shown), we cannot rule out an effect that could potentially skew the comparison.

This study shows that the administration of two doses of PCV7 to HIV+ individuals does not have a detrimental effect on VL or CD4+ T-cell counts in HIV+ individuals, regardless of whether they receive cART therapy. Based on these findings, the initial hypothesis of the excess deaths on the vaccine group observed in the original study being the result of attrition due to higher loss to follow-up among the placebo remains a plausible explanation [2].

Acknowledgements

We thank the patients and staff of the Queen Elizabeth Central Hospital Malawi. Work was supported by the Malawi Liverpool Wellcome Trust Clinical Research Unit and by Wellcome Trust award 061230.

Contributions

NF was the lead investigator in the original double-blind randomized placebo controlled trial that generated the data presented in this work. AIP and NF conceived the study. AIP contributed to data analysis, and both authors contributed to manuscript writing. All authors approved the final manuscript.

Conflict of interest

None declared.

References

[1] Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007;20(1):11–5.
[2] French N, Gordon SB, Mwalikomo T, White SA, Mwafailirwa C, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362(9):812–22.
[3] Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001;20(3–4):545–53.
[4] Lu CL, Chang SY, Sun HY, Liu WC, Tseng YT, Hsieh CY, et al. Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy. J Formos Med Assoc 2012;111(8):445–51.
[5] Madhi SA, Nunes MC. The potential impact of pneumococcal conjugate vaccine in Africa: considerations and early lessons learned from the South African experience. Hum Vac Immunother 2016;12(2):314–25.
[6] Geretti AM, Amendola A, Zappa A, Pariani E, Monguzzi A, Colzani D. Risks and benefits of influenza and pneumococcal vaccination in HIV-positive adults. Vaccine 2016;34(17):1989–99.
[7] Centers for Disease C, Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013;62(25):521–4.
[8] Keller M, Deveikis A, Cutillar-Garcia M, Gagajena A, Elkins K, Plaeger S, et al. Improved seroreactivity and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med 2012;13(4):207–18.
[9] Calmy A, Bell M, Nguyen A, Combescurc D, Delhumeau C, Meier S, et al. Strong seroreological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. AIDS 2013;17(4):207–18.
[10] Cheeseman SH, Davare RE, Ellison 3rd RT. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med 1996;334(19):1272.
[11] Stanley SK, Ostrowski MA, Justement JS, Gantri K, Hedaya S, Mannix M, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334(19):1223–30.
[12] Ceravolo A, Orsi A, Parodi V, Ansaldi F. Influenza vaccination in HIV-positive subjects: latest evidence and future perspective. J Prev Med Hyg 2013;54(1):1–10.
[13] Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine 2004;22(15–16):2006–12.
[14] Santos J, Palacios R, Ruiz J, Gonzalez M, Marquez M. Comparative trial of the effect of pneumococcal vaccine on viral load and CD4+ lymphocytes in asymptomatic and antiretrovirally naive HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002;21(6):488–9.
[15] Tanzi E, Amendola A, Zappa A, Pariani E, Monguzzi A, Coltani D. Risks and benefits of influenza and pneumococcal immunization in HIV-1 infected individuals. Ann Ig 2003;15(5):567–73.
[16] Brichacek B, Swindells J, Janoff EN, Pirraccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996;174(6):1191–9.
[17] Keller M, Deveikis A, Cutillar-Garcia M, Gagajena A, Elkins K, Plaeger S, et al. Pneumococcal and influenza immunization and human immunodeficiency virus load in children. Pediatr Infect Dis J 2000;19(7):613–8.
[18] Negredo E, Domingo P, Sanbeat MA, Rabella N, Vazquez G. Effect of pneumococcal vaccine on plasma HIV-1 RNA of stable patients undergoing effective highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2001;20(4):287–8.
[19] O’Brien WA, Grovit-Ferbas K, Namazi A, Ocak-Derici S, Wang HJ, Park J, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86(3):1082–9.